Physician profile
Nancy Sondgeroth
NPI 1770950842
$9,956.02
in general payments reported to CMS, 2019-2025
42 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,157 · 2022: $1,782 · 2023: $2,020 · 2024: $2,399 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,017.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,627.21 | 2021-2025 | |
| Lilly USA, LLC | $1,137.95 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,043.33 | 2021-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $709.96 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Nestle Healthcare Nutrition INC. | $598.37 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $395.36 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $313.36 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $309.98 | 2023-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $233.66 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $220.79 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.02 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $180.36 | 2021-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $170.39 | 2022-2025 | Zoryve, Seglentis |
| Novartis Pharmaceuticals Corporation | $155.75 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $131.28 | 2022-2025 | Gvoke Hypopen |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Sondgeroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.